Table 2.

Frequency and Outcomes of Predictive Marker Testing in Patients With Advanced Lung Adenocarcinoma (N = 758)

	EGFR	ALK	PD-L1
Number tested, n (%)	701 (92)	606 (80)	659 (87)
% with successful testing	98	99	95
Results	10% with sensitizing mutation	4.0% with rearrangement present	TPS < 1%	33%
			TPS 1%–49%	24%
			TPS ≥ 50%	38%

PD-L1, programmed death-ligand 1; TPS, tumor proportion score